Regulatory Affairs

International standards

ISO 15378 Standard
International Standard for Phytosanitary Measures 15 (ISPM 15) on wood materials

Pharmacopoeial guidance

European Pharmacopeia: Chapter 3.2.1
United States Pharmacopeia: USP <660>
Japanese Pharmacopeia: Chapter 7.01 method 1
Chinese Pharmacopeia: YBB

EU Regulations and Directive

EU Directive 94/62/EC on “Packaging and packaging waste”
EU Regulation 1907/2006/EC (REACH Regulation) on “Registration, Evaluation, Authorisation and Restriction of Chemicals”
EU Regulation 1935/2004/EC on “materials and articles intended to come into contact with food”
EU Directive 84/500/EC and its amendments on “ceramic articles intended to come into contact with foodstuffs”
EU Note for guidance EMA/410/01 on “minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products”

About us

Key facts

Business data

Turnover: 450 M€ (2024)

Global production capacity:
+ 8 Million vials per day

5 plants
7 furnaces
1 sorting facility
1 decoration workshop

Geographical areas: worldwide scope
90 agents & distributors
10 sales offices

Products’ categories & market applications:

Parenteral: molded injectable vials, tubular injectable vials, infusion bottles, ampoules
Oral: syrup bottles, tablet bottles, aerosol bottles, single dose bottle, droppers, bottles for antibiotics with filling mark
Baby bottles
Nasal bottles
Diagnostic bottles
Special needs: New designs & Innovation, plastic coating & printing, internal siliconization, ready-to-use, complete packs

Vials are carefully designed and manufactured with the highest integrity, ideally suited to a diverse range of application needs.

Social data

3063 employees
30% of women in top
management positions

245 person recruited in 2023
25,5 hours of training per employee per year

Environmental data

-18%
water consumption

-1,5%
GHG emissions on our European perimeter

+ 41%
of recycled waste

Discover the full CSR report

Milestones

2023

Our CSR strategy

To minimize the impact of our business on the environment, we are prioritizing decarbonization. Our goal is to lead the pharmaceutical glass manufacturing industry with our decarbonization efforts, with the intention of reducing CO2 emissions by 35% by 2030 and by 65% by 2040. SGD Pharma is SBTI committed and currently working on the 1.5°C scenario decarbonation pathway validation including our scope 3 emissions.

2023

Tubular and Corning partnership

SGD Pharma announced a joint venture with Corning to adopt the company’s Velocity® Vial coating technology and manufacture high-quality tubular vials at a new tube manufacturing facility in construction at SGD Pharma’s Vemula India production site.

This collaboration will help pharma companies respond to increasingly complex capacity and quality issues while meeting global demand for critical medicines. We broke ground on the $60M site in June 2023.

2022

Olivier Rousseau appointed as new Chief Executive Officer

2022

Inauguration of SGD Pharma India plant’s Unit V, fully dedicated to tubular glass packaging (capacity of 1 billion pieces by 2024).

2022

The United Nations (UN) recognizes glass as an essential material and that this year, its contribution to society will be honored through the International Year of Glass 2022. SGD Pharma, as an official sponsor of the UN International Year of the Glass, will be spotlighting glass and its role in health and wellbeing.

2021

PAI Partners (PAI), a leading European private equity firm, becomes SGD Pharma new shareholder.

2021

Ecovadis Platinum medal - The group was awarded the Ecovadis Platinum medal, its Chinese plant and its subsidiary Embelia were both awarded the Silver medal.

2021

Introduction of Type I molded glass enhanced offer: three distinct solutions - AXess, AXecure and AXpert - to help customers make an optimized choice, well-matched for specific requirements.

2021

SGD Pharma starts a major Sucy-en-Brie plant development project, investing over 31M€ to rebuild one of the furnaces and modernize the site.

2020

Introduction of Ensiemo, the new complete child-resistant packaging solution for CBD oils. Combining the company’s extensive pharmaceutical packaging expertise with the need for compliant, safe packaging for CBD oils, SGD Pharma has developed its first complete packaging solution & services, Ensiemo: a wide range of dropper bottles and dropper, in clear or amber glass.

2019

As part of its continuous improvement program, SGD Pharma optimized in 2020 the clear Type I glass composition of its best-in-class manufacturing plant at Saint-Quentin-Lamotte. This implementation provides a more robust process to improve the stability of the glass quality, improves the chemical resistance to reduce interaction with sensitive drug formulation and answers to stricter regulatory requirements.

2018

Introduction of Sterinity. The Sterinity platform in partnership with Stevanato Group – a recognized RTU platform for injectable vials by the pharmaceutical industry - offers high quality pre-sterilized Type I molded glass to speed up aseptic filling processes and reduces time-to-market for high value parenteral drugs.

2017

India plant's new Unit V is fully operational and 100% dedicated to our tubular product range.

2017

Launch of Clareo. This new innovative range of vials offers a combination of homogeneous wall thickness and superior cosmetic quality, which is unique for the molded glass Type II market. Improved mechanical resistance, significant reduction in the breakage rate and improved inspectability are the main characteristics of Clareo.

2017

SGD Pharma unveils its new identity. The new mission, vision and guiding principles support an ambitious growth strategy and a long-term vision for SGD Pharma.

2016

JIC (China Jianyin Investment Ltd) becomes SGD Group new shareholder.

2015

The new plant at Saint-Quentin-Lamotte produces its first glass vial on September 11th. December 21st marks the end of the pharmaceutical glass production at Mers-les-Bains after 57 years dedicated to this activity.

2014

New manufacturing factory in Picardie at Saint-Quentin-Lamotte. SGD launched the newest, most modern plant in the world to manufacture molded glass pharmaceutical packaging. The construction lasted 13 months. The 13-hectare site benefits from a state-of-the art equipment (electrical and oxy-gaz furnaces) enabling an outage daily capacity of 1 million bottles and 20.000 tons per year.

2013

The acquisition of an India-based manufacturer of Type I allows SGD Pharma to enter the tubular conversion market and to serve the fast-growing Indian pharmaceutical market.

2011

Introduction of EasyLyo. EasyLyo provides a stronger packaging that is more resistant and suitable to extreme conditions encountered during the lyophilization process. EasyLyo is a range of Type I glass vials combining the strength of molded glass with superior cosmetic quality and weight reduction.

2010

Oaktree Capital Management Ltd, an American investment firm, enters the Group’s capital on February 4th.

2008

Acquisition of the Société de Services Verriers (SSV) company in France, dedicated to the sorting of pharmaceutical containers, which is a new activity for SGD Pharma.

2007

Saint-Gobain Desjonquères becomes SGD Group. SGD Pharma is the first molded glass manufacturer to obtain the ISO 15378 certifications for all its pharmacy sites.

2005

U-Save launch. The U-Save range is dedicated to nasal applications. The specific design of the U-Save molded vials provides 100% of product recovery for high value nasal spray drugs. Can be customised with plastic coating and/or decoration.

1972

The acquisition of the Henri Desjonquères company by Saint-Gobain gives birth to Saint-Gobain Desjonquères, increasing its number of manufacturing sites worldwide: Kipfenberg (Germany), Santa Marina (Brazil), La Granja (Spain).

1958

The furnace 4 at the Mers-les-Bains (France) factory is dedicated to the production of Type I molded glass.

1939

Automation of the Mers-les-Bains (France) factory with IS machines.

1917

Specialization of the factory in Sucy-en-Brie (France) in the production of pharmaceutical bottles in molded glass.

1896

Henri Desjonquères founds Verrerie du Tréport, a glass manufacture factory in Mers-les-Bains (France), primarily aimed at the luxury perfumery market. The molded glass bottles are hand-blown.

Corporate Strategy

Discover SGD Pharma corporate strategy, mission and values.

Innovations

One of the keys to SGD Pharma’s leadership position in the glass industry has always been its drive to continually innovate.

Markets

Use our sector-specific webpages to find the best glass packaging solution...

Corporate strategy

OUR MISSION

Improve and protect patient’s health by providing high quality, reliable, and innovative primary glass packaging to our pharmaceutical customers

OUR VALUES

DEVELOP PEOPLE & TALENTS

We train, develop and invest in our people

We strive to create a positive work atmosphere

We recognize both leadership and expertise as career paths to grow in the company

OUR VALUES

PARTNER WITH THE CUSTOMER

We build long-term relationships with our customers

We are agile and responsive to customer’s needs

We optimize customer experience by being reliable and transparent

We innovate in collaboration with our customers to improve our offering

OUR VALUES

COMMIT TO PATIENT SAFETY

We understand our critical role in delivering drugs to patients safely

We put the highest focus on the quality provided to our customers

We consistently apply GMP standards

Innovations

One of the keys to SGD Pharma’s leadership position in the glass industry has always been its drive to continually innovate.

Quality Policy

SGD Pharma is committed to improving and protecting patient’s health...

Sustainability

SGD Pharma men and women are daily involved to contribute to satisfy our customers as well as to support sustainable development with focus on three main axes: our people, our business values, our environmental impacts.

Protecting children with lifesaving packaging

An evaluation of current and future child-resistant packaging trends in the pharmaceutical industry

Understand the evolving child-resistant packaging market and current regulations

Despite a reduction in cases in recent years, unintentional child poisoning remains a considerable risk in the home, with over-the-counter and prescription medicines presenting the greatest risk. Patients and stakeholders are calling upon the pharmaceutical industry to recognize the importance of child-resistant closures (CRCs) in medical packaging that is effective at preventing young children opening medication, while remaining accessible to senior patients.

Download PDF

Please enter your details and we’ll email your free white paper:

Title *

Mr.

Ms.

Last name

First name

Phone

Company

Position

By ticking this box, I agree to the collection and use by SGD Pharma of my personal data listed above in order to evaluate my application, in accordance with the data privacy policy

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

* Required fields

Navigating the regulatory landscape for cannabidiol (CBD) packaging

A global pharmaceutical packaging perspective – now including more countries!

Discover the latest global regulatory updates in the fast-moving CBD industry

The cannabidiol (CBD) market continues to grow rapidly, with regulations varying across different geographies and undergoing continuous updates. CBD manufacturers must not only navigate the CBD regulatory landscape, but that of cannabis itself, as well as pharmaceutical and food packaging and labelling, making it one of the most complex markets to operate in.

Download PDF

Please enter your details and we’ll email your free white paper:

Title *

Mr.

Ms.

Last name

First name

Phone

Company

Position

By ticking this box, I agree to the collection and use by SGD Pharma of my personal data listed above in order to evaluate my application, in accordance with the data privacy policy

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

* Required fields

Increasing flexibility in pharmaceutical packaging for aseptic filling

Learn how to achieve true flexibility and compliance in aseptic fill/ finish lines.

Ready-to-use (RTU) glass containers are enabling Pharma Companies to keep pace with the growing complex biologics and other specialty drugs market. By increasing flexibility, reducing time-to-market and total cost of ownership (TCO), and preserving safety and quality standards of the system, RTU molded glass vials now offer a new choice in aseptic manufacturing processes and technologies.

Download PDF

Please enter your details and we’ll email your free white paper:

Title *

Mr.

Ms.

Last name

First name

Phone

Company

Position

By ticking this box, I agree to the collection and use by SGD Pharma of my personal data listed above in order to evaluate my application, in accordance with the data privacy policy

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

* Required fields

On the Spot…Christophe Nicoli | Glass Worldwide Magazine

Source: Glassworldwide Magazine - 4/30/2022

The Pharmaceutical Post - May 2022

SGD Pharma launches industry first Ready-to-Use sterile 100 ml molded glass vials in SG® EZ-fill packaging technology

Source: The Pharmaceutical Post - May 2022

A3P TUNISIE - 12 TO 13 MAY - BOOTH 5

Stand No. :

Visiter le site web

SGD Pharma Zhanjiang was awarded ISO50001 certificate

Zhanjiang Plant has achieved the ISO 50001:2018 international energy management system certification issued by SGS in February 2022. Our company always adheres to the long-term commitment to sustainable development and makes efforts and contributions to creating a better environment and future.

Subscribe to